Yoo Sangjun, You Dalsan, Jeong In Gab, Song Cheryn, Hong Bumsik, Hong Jun Hyuk, Ahn Hanjong, Kim Choung-Soo
Department of Urology, Seoul National University Boramae Medical Center, Seoul, Korea.
Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea.
J Cancer Res Clin Oncol. 2017 Sep;143(9):1845-1851. doi: 10.1007/s00432-017-2430-6. Epub 2017 Apr 27.
We compared the oncological outcomes of papillary renal cell carcinoma (pRCC) with clear cell renal cell carcinoma (ccRCC) after partial nephrectomy (PN) in patients with pathologic T1a RCC.
After excluding patients with synchronous multiple renal tumors, familial RCC, and pathologic stage T1b or above, 759 patients with ccRCC and 84 patients with pRCC were included. We assessed the impact of histologic subtypes on oncologic outcomes after PN in patients with pathologic T1a RCC (median follow-up duration, 67 months).
There was no difference in patient and tumor characteristics between the 2 groups, except Fuhrman grade (p = 0.006). Kaplan-Meier analysis identified 5-year recurrence-free survival of 98.7 and 95.6% in patients with ccRCC and pRCC, respectively. However, 10-year recurrence-free survival in patients with ccRCC and pRCC was 96.1 and 73.0%, respectively (p < 0.001). Recurrence ≥5 years post surgery was more common in patients with pRCC compared with those with ccRCC (0.3 vs. 4.8%; p < 0.001). In multivariate analysis, pRCC [hazard ratio (HR) 5.309; p = 0.001] was a significant risk factor for recurrence after PN in patients with pathologic T1a RCC, in addition to larger tumor size (HR 1.861; p = 0.038) and Fuhrman grade ≥3 (HR 5.176; p = 0.003).
In patients with pathologic T1a RCC, recurrence after PN occurred more commonly in pRCC compared with ccRCC. As over half of the recurrence cases in patients with pRCC occurred ≥5 years post surgery, a longer follow-up time is required, even for those with pathologic stage T1a disease.
我们比较了病理T1a期肾细胞癌患者行部分肾切除术后,乳头状肾细胞癌(pRCC)与透明细胞肾细胞癌(ccRCC)的肿瘤学结局。
排除同时性多发肾肿瘤、家族性肾细胞癌以及病理分期为T1b或更高分期的患者后,纳入759例ccRCC患者和84例pRCC患者。我们评估了组织学亚型对病理T1a期肾细胞癌患者行部分肾切除术后肿瘤学结局的影响(中位随访时间为67个月)。
两组患者及肿瘤特征无差异,但Fuhrman分级有差异(p = 0.006)。Kaplan-Meier分析显示,ccRCC和pRCC患者的5年无复发生存率分别为98.7%和95.6%。然而,ccRCC和pRCC患者的10年无复发生存率分别为96.1%和73.0%(p < 0.001)。与ccRCC患者相比,pRCC患者术后≥5年复发更为常见(0.3%对4.8%;p < 0.001)。多因素分析显示,除肿瘤较大(风险比[HR] 1.861;p = 0.038)和Fuhrman分级≥3(HR 5.176;p = 0.003)外,pRCC(HR 5.309;p = 0.001)是病理T1a期肾细胞癌患者行部分肾切除术后复发的重要危险因素。
在病理T1a期肾细胞癌患者中,与ccRCC相比,pRCC患者行部分肾切除术后复发更为常见。由于pRCC患者超过一半的复发病例发生在术后≥5年,因此即使是病理分期为T1a期的患者也需要更长的随访时间。